Gluz, Oleg, Nitz, Ulrike, Kolberg-Liedtke, Cornelia, Prat, Aleix ORCID: 0000-0003-2377-540X, Christgen, Matthias, Kuemmel, Sherko, Mohammadian, Mohammad Parsa, Gebauer, Daniel, Kates, Ronald, Pare, Laia ORCID: 0000-0002-4904-558X, Grischke, Eva-Maria, Forstbauer, Helmut, Braun, Michael, Warm, Mathias, Hackmann, John, Uleer, Christoph, Aktas, Bahriye, Schumacher, Claudia, Wuerstlein, Rachel, Graeser, Monika, Pelz, Enrico, Jozwiak, Katarzyna ORCID: 0000-0002-9614-6586, Zu Eulenburg, Christine, Kreipe, Hans Heinrich and Harbeck, Nadia (2022). De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial. Clin. Cancer Res., 28 (22). S. 4995 - 5004. PHILADELPHIA: AMER ASSOC CANCER RESEARCH. ISSN 1557-3265

Full text not available from this repository.

Abstract

Purpose: Although optimal treatment in early triple-negative breast cancer (TNBC) remains unclear, de-escalated chemother-apy appears to be an option in selected patients within this aggressive subtype. Previous studies have identified several pro -immune factors as prognostic markers in TNBC, but their predictive impact regarding different chemotherapy strategies is still controversial.Experimental Design: ADAPT-TN is a randomized neoadju-vant multicenter phase II trial in early patients with TNBC (n = 336) who were randomized to 12 weeks of nab-paclitaxel 125 mg/m2 thorn gemcitabine or carboplatin d 1,8 q3w. Omission of further (neo-) adjuvant chemotherapy was allowed only in patients with patho-logical complete response [pCR, primary endpoint (ypT0/is, ypN0)]. Secondary invasive/distant disease-free and overall survival (i/dDFS, OS) and translational research objectives included quantification of a predictive impact of markers regard-ing selection for chemotherapy de-escalation, measured by gene expression of 119 genes (including PAM50 subtype) by nCounter platform and stromal tumor-infiltrating lymphocytes (sTIL).Results: After 60 months of median follow-up, 12-week-pCR was favorably associated (HR, 0.24; P = 0.001) with 5y-iDFS of 90.6% versus 62.8%. No survival advantage of carboplatin use was observed, despite a higher pCR rate [HR, 1.04; 95% confidence interval (CI), 0.68-1.59]. Additional anthracycline-containing che-motherapy was not associated with a significant iDFS advantage in pCR patients (HR, 1.29; 95% CI, 0.41-4.02). Beyond pCR rate, nodal status and high sTILs were independently associated with better iDFS, dDFS, and OS by multivariable analysis.Conclusions: Short de-escalated neoadjuvant taxane/platinum-based combination therapy appears to be a promising strategy in early TNBC for using pCR rate as an early decision point for further therapy (de-) escalation together with node-negative status and high sTILs.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Gluz, OlegUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Nitz, UlrikeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kolberg-Liedtke, CorneliaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Prat, AleixUNSPECIFIEDorcid.org/0000-0003-2377-540XUNSPECIFIED
Christgen, MatthiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kuemmel, SherkoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Mohammadian, Mohammad ParsaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gebauer, DanielUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kates, RonaldUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pare, LaiaUNSPECIFIEDorcid.org/0000-0002-4904-558XUNSPECIFIED
Grischke, Eva-MariaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Forstbauer, HelmutUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Braun, MichaelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Warm, MathiasUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Hackmann, JohnUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Uleer, ChristophUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Aktas, BahriyeUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Schumacher, ClaudiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Wuerstlein, RachelUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Graeser, MonikaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Pelz, EnricoUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Jozwiak, KatarzynaUNSPECIFIEDorcid.org/0000-0002-9614-6586UNSPECIFIED
Zu Eulenburg, ChristineUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Kreipe, Hans HeinrichUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Harbeck, NadiaUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-695995
DOI: 10.1158/1078-0432.CCR-22-0482
Journal or Publication Title: Clin. Cancer Res.
Volume: 28
Number: 22
Page Range: S. 4995 - 5004
Date: 2022
Publisher: AMER ASSOC CANCER RESEARCH
Place of Publication: PHILADELPHIA
ISSN: 1557-3265
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
TUMOR-INFILTRATING LYMPHOCYTES; EVENT-FREE SURVIVAL; PHASE-II TRIAL; PLUS CARBOPLATIN; NAB-PACLITAXEL; 6 CYCLES; EXPRESSION; CYCLOPHOSPHAMIDE; ASSOCIATION; DOXORUBICINMultiple languages
OncologyMultiple languages
URI: http://kups.ub.uni-koeln.de/id/eprint/69599

Downloads

Downloads per month over past year

Altmetric

Export

Actions (login required)

View Item View Item